Researchers are developing a new class of drugs called antisense oligonucleotides (ASOs) that work by blocking the production of harmful proteins involved in Alzheimer's disease and other dementias. These targeted therapies represent a shift in how scientists approach neurodegenerative diseases, moving away from broad treatments toward precision medicine that interferes with the specific molecular processes driving cognitive decline.

Timothy M. Miller, MD, PhD, the David Clayson Professor of Neurology at Washington University School of Medicine, has been awarded the 2026 Potamkin Prize for Research in Pick's, Alzheimer's, and Related Diseases, one of the most prestigious international honors in dementia research. Miller received the award in April at the American Academy of Neurology's annual meeting in Chicago.

What Are Antisense Oligonucleotides and How Do They Work?

Antisense oligonucleotides are short strands of genetic material designed to interfere with the production of harmful proteins. Rather than trying to remove proteins that have already accumulated in the brain, ASOs work upstream by preventing those proteins from being made in the first place. This approach has proven successful in treating other neurological conditions and is now being adapted for dementia.

Miller's pioneering work with ASOs led to the FDA approval of tofersen, a drug that blocks production of the toxic protein causing a rare form of ALS (amyotrophic lateral sclerosis). This success demonstrated that the ASO approach could translate from laboratory research into effective treatments for patients with neurodegenerative diseases.

How Is This Approach Being Applied to Alzheimer's Disease?

Miller's laboratory developed an ASO strategy specifically targeting tau, a protein that accumulates abnormally in Alzheimer's disease and other dementias like Pick's disease. Tau tangles are believed to contribute significantly to the memory loss and cognitive decline characteristic of these conditions. The ASO based on this research is currently in a large Phase 2 clinical trial in people with early Alzheimer's disease, with results expected this year.

This represents a meaningful shift in dementia treatment strategy. Rather than focusing solely on amyloid, another protein implicated in Alzheimer's, researchers are now targeting multiple pathways that drive neurodegeneration. By blocking tau production early in the disease process, scientists hope to slow or stabilize the cognitive decline that typically progresses in Alzheimer's patients.

Steps to Understanding Emerging Dementia Treatments

• Protein Targets: Modern dementia research focuses on specific proteins like tau and amyloid that accumulate in the brain and drive cognitive decline, rather than treating dementia as a single condition.
• Mechanism of Action: Antisense oligonucleotides work by preventing harmful proteins from being produced in the first place, offering a preventive approach rather than trying to remove proteins after they have already accumulated.
• Clinical Development: New treatments move through phases of testing, with Phase 2 trials evaluating whether a drug works in larger patient groups before advancing to broader use.
• Precision Medicine: Targeted therapies are designed to interfere with the specific molecular processes driving individual neurodegenerative diseases, allowing for more personalized treatment approaches.

Miller's recognition with the Potamkin Prize reflects his decades of work translating basic neuroscience into clinical therapies. The award is presented jointly by the American Academy of Neurology and the American Brain Foundation and is funded through the philanthropy of the Potamkin family. It specifically honors scientists who have made major contributions to understanding the causes of Pick's disease, Alzheimer's disease, and related dementias, and who have advanced efforts to prevent, treat, and cure these neurodegenerative diseases.

"The Potamkin Prize is a tremendous honor, and I am deeply grateful to my colleagues, collaborators and especially the participants and families involved in research," said Timothy M. Miller.

Timothy M. Miller, MD, PhD, David Clayson Professor of Neurology at Washington University School of Medicine

Miller is one of 11 members of the Washington University School of Medicine Department of Neurology selected to receive 2026 American Academy of Neurology awards. During the conference, he delivered a presentation on his work as part of a session titled "New Perspectives on Alzheimer's Therapeutics," highlighting the growing momentum in developing new approaches to dementia treatment.

The upcoming Phase 2 trial results for the tau-targeting ASO are particularly significant because they will provide the first large-scale evidence of whether this approach can meaningfully slow cognitive decline in early Alzheimer's disease patients. If successful, this could open new treatment pathways for millions of people at risk for or living with dementia, offering hope for interventions that go beyond current symptomatic treatments.